The Public Health Agency of Canada says it is not providing Novavax's COVID-19 vaccine this respiratory virus season, citing ...

Shares of Novavax Inc. NVAX shed 5.04% to $12.63 Monday, on what proved to be an all-around great trading session for the ...

In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...

On Friday, Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $13.3 which represents a slight increase of $1.15 or 9.47% from the prior close of $12.15. The stock opened at $12.32 and ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Some people are making it their mission to get Novavax, rather than Pfizer or Moderna, for their COVID booster.

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.8 which represents a decrease of $-0.11 or -0.85% from the prior close of $12.91. The stock opened at $13.01 and touched a low ...

In the most recent trading session, Novavax (NVAX) closed at $12.80, indicating a -0.85% shift from the previous trading day.

The Food and Drug Administration (FDA) has authorized the emergency use of the Novavax COVID-19 Vaccine, Adjuvanted.